Histone deacetylase (HDAC) inhibition modulates intracellular deoxynucleotides (dNTP) pools and potentiates the antitumor effects of the ribonucleotide reductase (RR) inhibitor 3’-Methyl-adenosine (3’-Me-Ado) in promyelocitic leukaemia cell lines.